[Percutaneous puncture biopsy of the lung (report of 100 cases)].

C. Wang

Abstract:

What problem does this paper attempt to address?

A Systematic Review of Current Applications of Fecal Microbiota Transplantation in Horses

Maimaiti Tuniyazi,Wenqing Wang,Naisheng Zhang

DOI: https://doi.org/10.3390/vetsci10040290

IF: 2.518

2023-04-13

Veterinary Sciences

Abstract:Fecal microbiota transplantation (FMT) is a technique involving transferring fecal matter from a healthy donor to a recipient, with the goal of reinstating a healthy microbiome in the recipient’s gut. FMT has been used in horses to manage various gastrointestinal disorders, such as colitis and diarrhea. To evaluate the current literature on the use of FMT in horses, including its efficacy, safety, and potential applications, the authors conducted an extensive search of several databases, including PubMed, MEDLINE, Web of Science, and Google Scholar, published up to 11 January 2023. The authors identified seven studies that met their inclusion criteria, all of which investigated the FMT application as a treatment for gastrointestinal disorders such as colitis and diarrhea. The authors demonstrated that FMT was generally effective in treating these conditions. However, the authors noted that the quality of the studies was generally suboptimal and characterized by small sample sizes and a lack of control groups. The authors concluded that FMT is a promising treatment option for certain gastrointestinal disorders in horses. Nevertheless, more research is required to determine the optimal donor selection, dosing, and administration protocols, as well as the long-term safety and efficacy of FMT in horses.

veterinary sciences
The fecal microbiota of healthy donor horses and geriatric recipients undergoing fecal microbial transplantation for the treatment of diarrhea

Caroline A. McKinney,Bruno C. M. Oliveira,Daniela Bedenice,Mary-Rose Paradis,Melissa Mazan,Sophie Sage,Alfredo Sanchez,Giovanni Widmer

DOI: https://doi.org/10.1371/journal.pone.0230148

IF: 3.7

2020-03-10

PLoS ONE

Abstract:Fecal microbial transplantation (FMT), a treatment for certain gastrointestinal conditions associated with dysbiosis in people, is also empirically employed in horses with colitis. This study used microbiota high-throughput sequencing to compare the fecal microbial profile of healthy horses to that of geriatric microbial transplant recipients experiencing diarrhea and tested whether FMT restores microbiota diversity.To evaluate the effect of environment and donor characteristics on the intestinal microbiota, fecal samples were collected per rectum from 15 healthy young-adult (2–12 years) and 15 geriatric (≥20 years) horses. Additionally, FMT was performed for 3 consecutive days in 5 geriatric horses with diarrhea using feces from the same healthy donor. Fecal samples were collected from both donor and recipient prior to each FMT and from recipients 24 hours following the last FMT. The profile of the fecal bacterial microbiota was compared using 16S amplicon sequencing.In contrast to diet and farm location, age did not significantly affect the healthy equine fecal microbiota, indicating that both healthy geriatric and young-adult horses may serve as FMT donors. The fecal microbiota of horses with diarrhea was significantly more variable in terms of β-diversity than that of healthy horses. An inverse correlation between diarrhea score and relative abundance of Verrucomicrobia was identified in surviving FMT recipients. At study completion, the fecal microbiota of horses which responded to FMT had a higher α-diversity than prior to treatment and was phylogenetically more similar to that of the donor.

multidisciplinary sciences
Effects of fecal microbiota transplantation on clinical outcomes and fecal microbiota of foals with diarrhea

Jillian Bell,Sharanne L Radial,Rosemary S Cuming,Gareth Trope,Kristopher J Hughes

DOI: https://doi.org/10.1111/jvim.17185

Abstract:Background: Diarrhea in foals can be associated with disruption of the intestinal microbiota (dysbiosis). Effective management of intestinal dysbiosis in foals has not been demonstrated. Hypothesis/objectives: Fecal microbiota transplantation (FMT) in foals with diarrhea influences the intestinal microbiota and improves clinical and clinicopathological outcomes. Animals: Twenty-five foals <6 months of age with diarrhea and systemic inflammatory response syndrome at 3 veterinary hospitals. Methods: A prospective randomized placebo-controlled cohort study. Foals in the FMT group (n = 19) or control group (n = 9) received FMT or electrolyte solution once daily for 3 days. Fecal samples were obtained on Day 0 (D0), D1, D2, D3, and D7. Within group and between group data analyses were performed for clinical, clinicopathological, and microbiota variables. Results: Treatment had no effect on survival (FMT 79%; control 100%, P = .3) or resolution of diarrhea (FMT 68%; control 55%, P = .4). On D3, the white blood cell count of the FMT group was lower than the control group (D3 FMT group median 6.4 g/L [5-8.3 g/L]; D3 control group median 14.3 g/L [6.7-18.9 g/L] P = .04). Heart rate reduced over time in the FMT group (D0 median 80 bpm [60-150 bpm]; D2 median 70 bpm [52-110 bpm] [P = .005]; and D3 median 64, [54-102 bpm] [P < .001]). Phylum Verrucomicrobiota, genus Akkermansia, and family Prevotellaceae were enriched in the FMT group on D1 (linear discriminate analysis > 4). Conclusions and clinical importance: In foals with diarrhea, FMT appears safe and can be associated with some clinical and microbiota changes suggestive of beneficial effect.
Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Noortje G Rossen,John K MacDonald,Elisabeth M de Vries,Geert R D'Haens,Willem M de Vos,Erwin G Zoetendal,Cyriel Y Ponsioen

DOI: https://doi.org/10.3748/wjg.v21.i17.5359

IF: 5.374

2015-01-01

World Journal of Gastroenterology

Abstract:AIM: To study the clinical efficacy and safety of Fecal microbiota transplantation (FMT). We systematically reviewed FMT used as clinical therapy.METHODS: We searched MEDLINE, EMBASE, the Cochrane Library and Conference proceedings from inception to July, 2013. Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category, on an intention-to-treat basis.RESULTS: We included 45 studies; 34 on Clostridium difficile-infection (CDI), 7 on inflammatory bowel disease, 1 on metabolic syndrome, 1 on constipation, 1 on pouchitis and 1 on irritable bowel syndrome (IBS). In CDI 90% resolution of diarrhea in 33 case series (n = 867) was reported, and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial (RCT) (n = 16). In ulcerative colitis (UC) remission rates of 0% to 68% were found (n = 106). In Crohn's disease (CD) (n = 6), no benefit was observed. In IBS, 70% improvement of symptoms was found (n = 13). 100% Reversal of symptoms was observed in constipation (n = 3). In pouchitis, none of the patients (n = 8) achieved remission. One RCT showed significant improvement of insulin sensitivity in metabolic syndrome (n = 10). Serious adverse events were rare.CONCLUSION: FMT is highly effective in CDI, and holds promise in UC. As for CD, chronic constipation, pouchitis and IBS data are too limited to draw conclusions. FMT increases insulin sensitivity in metabolic syndrome.

gastroenterology & hepatology
Carbonate buffer mixture and fecal microbiota transplantation hold promising therapeutic effects on oligofructose-induced diarrhea in horses

Maimaiti Tuniyazi,Ruibo Tang,Xiaoyu Hu,Yunhe Fu,Naisheng Zhang

DOI: https://doi.org/10.3389/fvets.2024.1388227

2024-04-22

Abstract:Diarrhea is a common gastrointestinal disorder in horses, with diet-induced diarrhea being an emerging challenge. This study aimed to investigate the gut microbiota differences in healthy and diet-induced diarrheic horses and evaluate the effectiveness of fecal microbiota transplantation (FMT) and carbonate buffer mixture (CBM) as potential therapeutic approaches. Twenty healthy horses were included in the study, with four groups: Control, Diarrhea, CBM, and FMT. Diarrhea was induced using oligofructose, and fecal samples were collected for microbiota analysis. FMT and CBM treatments were administered orally using donor fecal matter, and formula mixture, respectively. Clinical parameters, serum levels, intestinal tissue histopathology, and fecal microbiota profiles were evaluated. The results showed that diarrhea induction disbalanced the gut microbiota with decreased diversity and richness, affected clinical parameters including elevated body temperature and diarrhea score, and decreased fecal pH, increased inflammatory responses such as increased serum LPS, IL-17A, lactic acid and total protein, and caused damage in the colon tissue. CBM and FMT treatments altered the gut microbiota composition, restoring it towards a healthier profile compared to diarrheic, restored the gut microbiota composition to healthier states, improved clinical symptoms including decreased body temperature and diarrhea score, and increased fecal pH, decreased inflammatory responses such as increased serum LPS, IL-17A, lactic acid and total protein, and repaired tissue damage. CBM and FMT Spearman correlation analysis identified specific bacterial taxa associated with host parameters and inflammation. FMT and CBM treatments showed promising therapeutic effects in managing oligofructose-induced diarrhea in horses. The findings provide valuable insights into the management and treatment of diarrhea in horses and suggest the potential of combined CBM and FMT approaches for optimal therapeutic outcomes.
Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease with Fecal Microbiota Transplantation: A Pilot Study

Xiaofei Qi,Xuewei Li,Ye Zhao,Xiaojin Wu,Feng Chen,Xiao Ma,Faming Zhang,Depei Wu

DOI: https://doi.org/10.3389/fimmu.2018.02195

IF: 7.3

2018-01-01

Frontiers in Immunology

Abstract:Patients with steroid refractory gastrointestinal (GI) tract graft- vs.-host disease (GvHD) face a poor prognosis and limited therapeutic options. To accurately assess the efficacy and safety of fecal microbiota transplantation (FMT) in treating steroid refractory GI tract GvHD, we conducted a pilot study involving eight patients. Having received FMTs, all patients' clinical symptoms relieved, bacteria enriched, and microbiota composition reconstructed. Compared to those who did not receive FMT, these eight patients achieved a higher progression-free survival. FMT can serve as a therapeutic option for GI tract aGVHD, but its effectiveness and safety need further evaluations.Clinical Trial Registration: NCT03148743.
Fecal Microbiota Transplantation: An Update on Clinical Practice

Kyeong Ok Kim,Michael Gluck

DOI: https://doi.org/10.5946/ce.2019.009

2019-03-31

Clinical Endoscopy

Abstract:Fecal microbiota transplantation (FMT) is an infusion in the colon, or the delivery through the upper gastrointestinal tract, of stool from a healthy donor to a recipient with a disease believed to be related to an unhealthy gut microbiome. FMT has been successfully used to treat recurrent Clostridium difficile infection (rCDI). The short-term success of FMT in rCDI has led to investigations of its application to other gastrointestinal disorders and extra-intestinal diseases with presumed gut dysbiosis. Despite the promising results of FMT in these conditions, several barriers remain, including determining the characteristics of a healthy microbiome, ensuring the safety of the recipient with respect to long-term outcomes, adequate monitoring of the recipient of fecal material, achieving high-quality control, and maintaining reasonable costs. For these reasons, establishing uniform protocols for stool preparation, finding the best modes of FMT administration, maintaining large databases of donors and recipients, and assuring that oral ingestion is equivalent to the more widely accepted colonoscopic infusion are issues that need to be addressed.
An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases

Karen M. J. Waller,Rupert W. Leong,Sudarshan Paramsothy

DOI: https://doi.org/10.1111/jgh.15731

2021-11-12

Journal of Gastroenterology and Hepatology

Abstract:Our understanding of the microbiome and its implications for human health and disease continues to develop. Fecal microbiota transplantation (FMT) is now an established treatment for recurrent Clostridioides difficile infection. There is also increasing evidence for the efficacy of FMT in inducing remission for mild-moderate ulcerative colitis. However, for other indications, data for FMT are limited, with randomized controlled trials rare, typically small and often conflicting. Studies are continuing to explore the role of FMT for many other conditions, including Crohn's disease, functional gut disorders, metabolic syndrome, modulating responses to chemotherapy, eradication of multidrug resistant organisms, and the gut-brain axis. In light of safety, logistical, and regulatory challenges, there is a move to standardized products including narrow spectrum consortia. However, the mechanisms underpinning FMT remain incompletely understood, including the role of non-bacterial components, which may limit success of novel microbial approaches.

gastroenterology & hepatology
Recombinant hypoallergens for immunotherapy of Parietaria judaica pollen allergy.

J. Asturias

DOI: https://doi.org/10.2741/3553

Frontiers in Bioscience

Abstract:Recombinant allergens are a promising alternative to crude allergen extracts for diagnosis and therapy of allergic diseases. Genetically modified allergen derivatives with reduced allergenic activity but retaining their immunogenicity have also been produced to increase safety and specificity of allergen-specific immunotherapy. When a limited number of allergens are responsible for most of the allergenic activity, fusion proteins comprising these major allergens can be used to simplify vaccine development. Three different allergen fusions of Par j 1 and Par j 2, the major allergens from Parietaria judaica, were characterized. Two of them (Q1 and Q2) showing reduced allergenicity but conserved immunogenicity represent suitable candidates for allergen-specific immunotherapy against P. judaica pollen allergy.
Safety profile and effects on the peripheral immune response of fecal microbiota transplantation in clinically healthy dogs

Mary Ann Lee,Maria Questa,Patrawin Wanakumjorn,Amir Kol,Bridget McLaughlin,Bart C Weimer,Agostino Buono,Jan S Suchodolski,Sina Marsilio

DOI: https://doi.org/10.1111/jvim.17061

Abstract:Background: Fecal microbiota transplantation (FMT) is increasingly used for gastrointestinal and extra-gastrointestinal diseases in veterinary medicine. However, its effects on immune responses and possible adverse events have not been systematically investigated. Hypothesis/objectives: Determine the short-term safety profile and changes in the peripheral immune system after a single FMT administration in healthy dogs. Animals: Ten client-owned, clinically healthy dogs as FMT recipients, and 2 client-owned clinically healthy dogs as FMT donors. Methods: Prospective non-randomized clinical trial. A single rectal enema of 5 g/kg was given to clinically healthy canine recipients. During the 28 days after FMT administration, owners self-reported adverse events and fecal scores. On Days 0 (baseline), 1, 4, 10, and 28 after FMT, fecal and blood samples were collected. The canine fecal dysbiosis index (DI) was calculated using qPCR. Results: No significant changes were found in the following variables: CBC, serum biochemistry, C-reactive protein, serum cytokines (interleukins [IL]-2, -6, -8, tumor necrosis factor [TNF]-α), peripheral leukocytes (B cells, T cells, cluster of differentiation [CD]4+ T cells, CD8+ T cells, T regulatory cells), and the canine DI. Mild vomiting (n = 3), diarrhea (n = 4), decreased activity (n = 2), and inappetence (n = 1) were reported, and resolved without intervention. Conclusions and clinical importance: Fecal microbiota transplantation did not significantly alter the evaluated variables and recipients experienced minimal adverse events associated with FMT administration. Fecal microbiota transplantation was not associated with serious adverse events, changes in peripheral immunologic variables, or the canine DI in the short-term.
Systematic Review: Faecal Microbiota Transplantation Therapy for Digestive and Nondigestive Disorders in Adults and Children

S. Sha,J. Liang,M. Chen,B. Xu,C. Liang,N. Wei,K. Wu

DOI: https://doi.org/10.1111/apt.12699

IF: 9.524

2014-01-01

Alimentary Pharmacology & Therapeutics

Abstract:BackgroundThere has been growing interest in the use of faecal microbiota transplantation (FMT) for the treatment of gastrointestinal and nongastrointestinal diseases.AimTo review systematically the reported efficacy and safety of FMT in the management of gastrointestinal and nongastrointestinal disorders in adults and children.MethodsThe systematic review followed Cochrane and PRISMA recommendations. Available articles were identified using three electronic databases in addition to hand searching and contacting experts. Inclusion criteria were any reports of FMT therapy written in English.ResultsA total of 844 patients who had undergone FMT were identified from 67 published studies. The most common indications were refractory/relapsing Clostridium difficile infection (CDI) (76.3%) and inflammatory bowel disease (IBD) (13.2%). There has been only one placebo-controlled trial, a successful trial in 43 patients with recurrent CDI. Seven publications report FMT in paediatric patients with a total of 11 treated, 3 with chronic constipation and the remainder with recurrent CDI or ulcerative colitis (UC). 90.7% of patients with refractory/relapsing CDI were cured and 78.4% of patients with IBD were in remission after FMT. FMT therapy could also be effective in treatment of some nongastrointestinal disorders such as chronic fatigue syndrome. The only reported serious adverse event attributed to the therapy was a case of suspected peritonitis.ConclusionsAlthough more controlled trials are needed, faecal microbiota transplantation therapy shows promise in both adults and children with gastrointestinal diseases such as CDI and IBD.
Clinical Application and Potential of Fecal Microbiota Transplantation

R.E. Ooijevaar,E.M. Terveer,H.W. Verspaget,E.J. Kuijper,J.J. Keller

DOI: https://doi.org/10.1146/annurev-med-111717-122956

2019-01-27

Annual Review of Medicine

Abstract:Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent Clostridioides difficile infection. FMT has become a more readily available and useful new treatment option as a result of stool banks. The current state of knowledge indicates that dysbiosis of the gut microbiota is implicated in several disorders in addition to C. difficile infection. Randomized controlled studies have shown FMT to be somewhat effective in treating ulcerative colitis, irritable bowel syndrome, and hepatic encephalopathy. In addition, FMT has been beneficial in treating several other conditions, such as the eradication of multidrug-resistant organisms and graft-versus-host disease. We expect that FMT will soon be implemented as a treatment strategy for several new indications, although further studies are needed.

medicine, research & experimental
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

Colleen R. Kelly,Stacy Kahn,Purna Kashyap,Loren Laine,David Rubin,Ashish Atreja,Thomas Moore,Gary Wu

DOI: https://doi.org/10.1053/j.gastro.2015.05.008

IF: 29.4

2015-07-01

Gastroenterology

Abstract:The community of microorganisms within the human gut (or microbiota) is critical to health and functions with a level of complexity comparable to that of an organ system. Alterations of this ecology (or dysbiosis) have been implicated in a number of disease states, and the prototypical example is Clostridium difficile infection (CDI). Fecal microbiota transplantation (FMT) has been demonstrated to durably alter the gut microbiota of the recipient and has shown efficacy in the treatment of patients with recurrent CDI. There is hope that FMT may eventually prove beneficial for the treatment of other diseases associated with alterations in gut microbiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to name a few. Although the basic principles that underlie the mechanisms by which FMT shows therapeutic efficacy in CDI are becoming apparent, further research is needed to understand the possible role of FMT in these other conditions. Although relatively simple to perform, questions regarding both short-term and long-term safety as well as the complex and rapidly evolving regulatory landscape has limited widespread use. Future work will focus on establishing best practices and more robust safety data than exist currently, as well as refining FMT beyond current "whole-stool" transplants to increase safety and tolerability. Encapsulated formulations, full-spectrum stool-based products, and defined microbial consortia are all in the immediate future.

gastroenterology & hepatology
Case Report: Oral Fecal Microbiota Transplantation in a Dog Suffering From Relapsing Chronic Diarrhea—Clinical Outcome and Follow-Up

Matteo Cerquetella,Andrea Marchegiani,Giacomo Rossi,Massimo Trabalza-Marinucci,Fabrizio Passamonti,Marco Isidori,Fabrizio Rueca

DOI: https://doi.org/10.3389/fvets.2022.893342

IF: 3.471

2022-07-04

Frontiers in Veterinary Science

Abstract:The present case report describes the effects of orally administered fecal microbiota transplantation (FMT) (frozen capsules) in a dog suffering from relapsing chronic diarrhea, needing a continuous low prednisolone dose to maintain the condition under acceptable control. Through FMT, we aimed at evaluating the possibility of improving the clinical score and/or reducing/suspending steroid administration. During a first period of strict monitoring (21 days), the canine inflammatory bowel disease activity index (CIBDAI) score passed from mild to clinically insignificant disease. Furthermore, two additional gastrointestinal signs that had been reported, bloating and episodes of painful defecation, rapidly improved (bloating) or even resolved (painful defecation). The patient was then followed for 18 months (to the authors' knowledge, the longest follow-up time ever reported in a dog), during which no serious relapses occurred and no increase in prednisolone dose was necessary. No adverse clinical effects were ever reported during monitoring. The present description provides a further experience increasing those already present in the veterinary literature, in which an agreement on how to use FMT has not yet been achieved although strongly needed and recommended.

veterinary sciences
P810 Fecal microbiota transplantation in Ulcerative rectocolitis

F Ferreira,M Sousa,M Melado,M Pacheco,L Trindade,F Lorentz,L Carmo,A Clara

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0940

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background The objective of this work was to carry out a systematic review of the literature to evaluate interventional trials that compare fecal microbiofa transplantation (FMT) with a control group and evaluate the incidence of remission of ulcerative colitis as an outcome. Methods The search was conducted using the database from PubMed, from February 2021 to April 2023. In all, 303 articles were found. After reading the titles, 43 articles were selected for the abstract reading. After all the analysis with inclusion and exclusion criteria, 7 articles were fully analyzed in the present study. Of the 7 selected studies, 71% (5/7) performed clinical trials. Results In all the studies, a total of 352 patients were submitted to the FMT, with a average of 63 participants per study. The age of the participants vary from 18 to 75 years old, with all the studies having an average age in the third or fourth decade. All articles included patients with clinical disease activity, and 85.7% used the Mayo severity index. Regarding the stool administered, in 71.4% of the studies the participants received frozen stool and the preparation was carried out with saline solution. The infusion was performed with colonoscopy on 85% (6/7) of the studies, however there was no standardized approach to the transplant protocol or preparation of the patients before the FMT. The association between the FMT and the clinical remission has been positive in 85% (6/7) of the studies. 4 of the 5 articles that evaluated the clinical response pointed to an improvement of the patients submitted to the transplant over the placebo group. The endoscopic remission were analyzed in all the 7 studies showing positive results in 43% (3/7) of them. The laboratory were performed in just 1 of the studies and they reported substantial improvement of the evaluated parameters of the FMT group. There was no significant difference between the risk of developing adverse effects between the FMT and the placebo groups. Conclusion The FMT has been shown to be effective on the induction of clinical remission of Ulcerative Colitis, however, clinical studies with greater scientific impact are needed to implement this new therapeutic modality.

gastroenterology & hepatology
T-cell activation: integration of signals from the antigen receptor and costimulatory molecules.

E. Robey,J. Allison

DOI: https://doi.org/10.1016/0167-5699(95)80140-5

1995-07-01

Abstract:
Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

Rohma Ghani,Despoina Chrysostomou,Lauren A Roberts,Madhumitha Pandiaraja,Julian R. Marchesi,Benjamin H. Mullish

DOI: https://doi.org/10.1080/19490976.2024.2423026

IF: 12.2

2024-11-07

Gut Microbes

Abstract:Faecal/intestinal microbiota transplant (FMT/IMT) is an efficacious treatment option for recurrent Clostridioides difficile infection, which has prompted substantial interest in FMT's potential role in the management of a much broader range of diseases associated with the gut microbiome. Despite its promise, the success rates of FMT in these other settings have been variable. This review critically evaluates the current evidence on the impact of clinical, biological, and procedural factors upon the therapeutic efficacy of FMT, and identifies areas that remain nebulous. Due to some of these factors, the optimal therapeutic approach remains unclear; for example, the preferred timing of FMT administration in a heavily antibiotic-exposed hematopoietic cell transplant recipient is not standardized, with arguments that can be made in alternate directions. We explore how these factors may impact upon more informed selection of donors, potential matching of donors to recipients, and aspects of clinical care of FMT recipients. This includes consideration of how gut microbiome composition and functionality may strategically inform donor selection criteria. Furthermore, we review how the most productive advances within the FMT space are those where clinical and translational outcomes are assessed together, and where this model has been used productively in recent years to better understand the contribution of the gut microbiome to human disease, and start the process toward development of more targeted microbiome therapeutics.

gastroenterology & hepatology,microbiology
An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases

Albert K Groen,Max Nieuwdorp

DOI: https://doi.org/10.15252/emmm.201607035

2016-11-10

EMBO Molecular Medicine

Abstract:Fecal microbiota transplantation (FMT) has had a long history in medicine for treating a number of human diseases. As early as during the 4th century BC, FMT was used in China to treat patients with food poisoning and diarrhea. Over time, the method became obsolete, particularly after the realization that hygiene plays an important role in preventing infectious diseases. It was not until the late 1950s that FMT garnered interest again when the first reports about its use to treat fulminant enterocolitis appeared in the scientific literature. However, FMT's breakthrough as the method of choice for the treatment of persistent Clostridium difficile infection (CDI) came only after a double‐blind randomized trial (van Nood et al, 2013), which demonstrated 94% efficacy of FMT compared with 31% after conservative treatment with vancomycin. Fecal microbiota transplantation (FMT) has had a long history in medicine for treating a number of human diseases. While it seems to work for persistent Clostridium difficile infections, results are variable for other disorders. A. Groen and M. Nieuwdorp's commentary sheds light on this issue.

medicine, research & experimental
Longitudinal evaluation of fecal microbiota transplantation for ameliorating calf diarrhea and improving growth performance

Hyun Sik Kim,Tae Woong Whon,Hojun Sung,Yun-Seok Jeong,Eun Sung Jung,Na-Ri Shin,Dong-Wook Hyun,Pil Soo Kim,June-Young Lee,Choong Hwan Lee,Jin-Woo Bae

DOI: https://doi.org/10.1038/s41467-020-20389-5

IF: 16.6

2021-01-08

Nature Communications

Abstract:Abstract Calf diarrhea is associated with enteric infections, and also provokes the overuse of antibiotics. Therefore, proper treatment of diarrhea represents a therapeutic challenge in livestock production and public health concerns. Here, we describe the ability of a fecal microbiota transplantation (FMT), to ameliorate diarrhea and restore gut microbial composition in 57 growing calves. We conduct multi-omics analysis of 450 longitudinally collected fecal samples and find that FMT-induced alterations in the gut microbiota (an increase in the family Porphyromonadaceae ) and metabolomic profile (a reduction in fecal amino acid concentration) strongly correlate with the remission of diarrhea. During the continuous follow-up study over 24 months, we find that FMT improves the growth performance of the cattle. This first FMT trial in ruminants suggest that FMT is capable of ameliorating diarrhea in pre-weaning calves with alterations in their gut microbiota, and that FMT may have a potential role in the improvement of growth performance.

multidisciplinary sciences
Storage of equine faecal microbiota transplantation solution has minimal impact on major bacterial communities and structure

J Bell,S Raidal,A Peters,K J Hughes

DOI: https://doi.org/10.1016/j.tvjl.2024.106220

Abstract:Management of diarrhoea in horses is usually non-specific and supportive. Faecal microbiota transplantations (FMT) are used to manage dysbiosis in horses with diarrhoea. There are few studies investigating the effects of storage on prepared FMT solutions. This study was an in vitro non-randomised controlled experiment that investigated the effects of FMT solution preparation and storage on the faecal microbiota. Fresh faeces were collected from five healthy adult horses and used for DNA extraction and preparation of FMT. From each FMT, seven aliquots were collected and DNA was extracted immediately after FMT preparation (0 hr), after storage at 4 °C for 24, 48 or 72 hours, and after storage at -20°C for 7 days, 14 days or 28 days. The extracted DNA was used for 16 S rRNA gene sequencing. The relative abundance, alpha diversity and beta diversity between fresh faeces and FMT 0 hr showed no differences (P ≥ 0.05). There were minimal changes in the microbiota of FMT stored at 4°C for up to 72 hours and -20°C for up to 28 days. The results of this study indicate that preparation of equine FMT solution has minimal effect on the microbiota in comparison to fresh faeces. FMT solution can be stored at 4°C for up to 3 days and -20°C for 28 days without major change in microbiota.

[Percutaneous puncture biopsy of the lung (report of 100 cases)].

A Systematic Review of Current Applications of Fecal Microbiota Transplantation in Horses

The fecal microbiota of healthy donor horses and geriatric recipients undergoing fecal microbial transplantation for the treatment of diarrhea

Effects of fecal microbiota transplantation on clinical outcomes and fecal microbiota of foals with diarrhea

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Carbonate buffer mixture and fecal microbiota transplantation hold promising therapeutic effects on oligofructose-induced diarrhea in horses

Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease with Fecal Microbiota Transplantation: A Pilot Study

Fecal Microbiota Transplantation: An Update on Clinical Practice

An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases

Recombinant hypoallergens for immunotherapy of Parietaria judaica pollen allergy.

Safety profile and effects on the peripheral immune response of fecal microbiota transplantation in clinically healthy dogs

Systematic Review: Faecal Microbiota Transplantation Therapy for Digestive and Nondigestive Disorders in Adults and Children

Clinical Application and Potential of Fecal Microbiota Transplantation

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

Case Report: Oral Fecal Microbiota Transplantation in a Dog Suffering From Relapsing Chronic Diarrhea—Clinical Outcome and Follow-Up

P810 Fecal microbiota transplantation in Ulcerative rectocolitis

T-cell activation: integration of signals from the antigen receptor and costimulatory molecules.

Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases

Longitudinal evaluation of fecal microbiota transplantation for ameliorating calf diarrhea and improving growth performance

Storage of equine faecal microbiota transplantation solution has minimal impact on major bacterial communities and structure